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Abstract
Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor
receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further
improve the selection of patients for this treatment. We assessed the influence of modification of KRAS by gene
copy number aberration (CNA) and microRNAs (miRNAs) in correlation to clinical outcome in mCRC patients treated
with cetuximab in combination with chemotherapy and bevacizumab.
Methods: Formalin-fixed paraffin-embedded primary tumour tissue was used from 34 mCRC patients in a phase III
trial, who were selected based upon their good (n = 17) or poor (n = 17) progression-free survival (PFS) upon
treatment with cetuximab in combination with capecitabine, oxaliplatin, and bevacizumab. Gene copy number at
the KRAS locus was assessed using high resolution genome-wide array CGH and the expression levels of 17 miRNAs
targeting KRAS were determined by real-time PCR.
Results: Copy number loss of the KRAS locus was observed in the tumour of 5 patients who were all good
responders including patients with a KRAS mutation. Copy number gains in two wild-type KRAS tumours were
associated with a poor PFS. In KRAS mutated tumours increased miR-200b and decreased miR-143 expression were
associated with a good PFS. In wild-type KRAS patients, miRNA expression did not correlate with PFS in a
multivariate model.
Conclusions: Our results indicate that the assessment of KRAS CNA and miRNAs targeting KRAS might further
optimize the selection of mCRC eligible for anti-EGFR therapy.
Background
Recent advances in our understanding of the specific sig-
nalling pathways of cancer cells have introduced targeted
therapy into treatment regimes for patients with meta-
static colorectal cancer (mCRC). Antibodies against the
epidermal growth factor receptor (EGFR), cetuximab
and panitumumab, have shown a survival benefit in
mCRC patients with KRAS wild-type tumours both as
monotherapy [1,2] and when added to chemotherapy
[3,4]. Patients with a tumour harbouring a KRAS codon
12 or 13 mutation are resistant to anti-EGFR therapy
[1,5]. Therefore the use of these antibodies is restricted
to patients with KRAS wild-type tumours. However,
within this subset not all patients respond to this treat-
ment, and therefore additional predictive markers are
needed. We have previously excluded a discordance in
KRAS mutation status between the primary tumour and
corresponding metastases as an explanation for the het-
erogeneous response rate in patients with KRAS wild-
type tumours [6]. In routine practice, KRAS mutations
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in codons 12 and 13 are tested, which comprise approxi-
mately 96% of the observed KRAS mutations [7]. Recent
data suggest that a codon 13 KRAS mutation has a dis-
tinct clinical behaviour and is not associated with cetuxi-
mab resistance [8]. Whether other KRAS mutations (like
codon 61) result in similar resistance to EGFR monoclo-
nal antibodies remains speculative [9]. A mutation in the
BRAF oncogene occurs in approximately 10% of mCRC
patients and is restricted to KRAS wild-type tumours,
and was first shown to have a negative predictive value
for anti-EGFR therapy [10]. Subsequently, we have
shown that a BRAF mutation predominantly has a
strong negative prognostic value [11]. Other biomarkers
in the PI3K and RAS/MAPK pathways [12-16], ligands
to the EGFR [17,18], and germline single nucleotide
polymorphisms [19-21] have not yet shown a predictive
value that can be used in clinical practice.
Point mutations in the KRAS oncogene lead to a sig-
nificantly increased RAS-GTPase activity, ultimately
resulting in the stimulation of cell proliferation and the
inhibition of apoptosis via the RAS/MAPK pathway [22].
However, in addition to oncogenic mutations, copy
number changes of the KRAS gene or posttranslational
factors may also be involved in the regulatory mechan-
ism of RAS-GTPase activity. Copy number aberrations
(CNA) occur throughout the tumour genome and are an
important mechanism in colorectal cancer development
[23]. Genome-wide studies in mCRC patients have iden-
tified loci that are associated with a poor prognosis [24]
and with the prediction of response to chemotherapy
[25]. However, little is known about the prevalence and
effect of CNA of the KRAS locus on chromosome
12p12.1. By using a TaqMan-based KRAS copy number
assay, KRAS amplifications were observed in approxi-
mately 2% of the 106 investigated colorectal primary
tumours [26]. In CRC cell lines, gains of the KRAS locus
were shown to be associated with an eleven-fold increase
in RAS-GTPase activity, which is comparable with the
twelve-fold increase caused by a codon 12 or 13 muta-
tion [27]. However, no data have been reported on CNA
affecting the KRAS locus and their possible association
with response to cetuximab.
In recent years, a rapidly expanding interest has mani-
fested on microRNAs (miRNAs). These single stranded
RNAs of 19–23 nucleotides regulate gene expression by
translational inhibition or mRNA degradation via imper-
fect base pairing to the 3’-untranslated region (3’UTR)
of their target mRNAs [28]. MiRNAs are involved in the
development of human cancer, and in case of dysregula-
tion they can act either as oncogenes or tumour sup-
pressors, depending on their target genes [29]. Recently
several miRNAs were identified that target KRAS, result-
ing in the suppression of cancer development [30-33].
KRAS contains multiple let-7 complementary sites,
allowing the let-7 family of miRNAs to act as a tumour
suppressor by regulating the KRAS mRNA [30,31]. Also
mir-18a and miR-143 directly recognize KRAS, and
downregulation of these miRNAs accelerates tumouri-
genesis by reversal of KRAS suppression [32]. The target-
ing effect of miR-18a on KRAS has been demonstrated in
colon cancer cell lines irrespective of KRAS mutation sta-
tus [33]. MiRNAs interfering with the RAS-signaling path-
way may have predictive value or may even serve as
targets for treatment. Currently no data are available on
the clinical relevance of miRNAs involved in KRAS activ-
ity in patients treated with cetuximab.
In this study we analyzed the KRAS copy number sta-
tus and the expression of miRNAs targeting KRAS in re-
lation to clinical outcome in mCRC patients treated with
first-line cetuximab-containing therapy.
Methods
Patients
The patients included in this study participated in the
CAIRO2 trial (CKTO 2005–02; ClinTrials.gov
NCT00208546) of the Dutch Colorectal Cancer Group
(DCCG) [34]. In this multicenter phase III trial, 755
mCRC patients were randomized between first-line
treatment with capecitabine (1000 mg/m2 bid.), oxalipla-
tin (130 mg/m2), and bevacizumab (7.5 mg/kg), or the
same schedule with the addition of weekly cetuximab
(250 mg/m2, after initial 400 mg/m2). Translational re-
search on tumour tissue was part of the informed con-
sent procedure. The primary end point of the study was
progression free survival (PFS), and secondary end
points were overall survival, response rate, and toxicity.
The median PFS in patients treated with cetuximab was
9.4 months (95% CI 8.4-10.5 months), which was signifi-
cantly shorter than the PFS of patients treated in the
group without cetuximab (median PFS 10.7 months,
95% CI 9.7-12.3 months, p = 0.01). Patients in the
cetuximab-group with a KRAS mutated tumour had a
significantly decreased median PFS compared to patients
with a KRAS wild-type tumour (8.1 versus 10.5 months,
respectively, p = 0.04).
For the current analysis we selected patients who had
been randomized to the cetuximab treatment arm,
received at least three treatment cycles, did not discon-
tinue treatment for other causes than disease progres-
sion, had a normal serum lactate dehydrogenase at
randomisation, and of whom formalin-fixed paraffin-
embedded (FFPE) material of the primary tumour as
well as normal tissue was available. Patients with a rectal
carcinoma and patients who had received preoperative
radiotherapy on the pelvis have been excluded for these
analyses. From this group the 17 best and 17 worst
responding patients were selected based on both
extremes of the PFS time. Throughout the article the
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terms good and poor responders are used, which does
not apply to response according to RECIST, but to the
patients with the longest and shortest PFS on
cetuximab-based treatment. This outcome parameter
was chosen for the current study because it is the best
reflection of the clinical trial upon which this analysis is
based. Next, especially with respect to targeted agents
PFS appears to be superior of response rate in terms of
clinical outcome.
DNA extraction and mutation analysis
Genomic DNA was extracted from 4–8 manually micro
dissected 50 μm sections of FFPE tissue as previously
described [35]. DNA concentration was determined
using the Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies Inc., Wilmington, USA). DNA
quality was assessed by performing a multiplex PCR
using 4 primer sets, resulting in fragments of 100, 200,
300 and 400 base pairs [36]. The KRAS mutation status
[35] and BRAF mutation status [11,12] were assessed by
sequencing analysis as previously described.
Assessment of the KRAS gene copy number and data
analysis
High-resolution genome-wide DNA copy number pro-
files were generated by array-based comparative genomic
hybridization (array CGH) using 720 k Whole-Genome
Tiling CGH arrays (Roche NimbleGen Inc., Madison,
USA). Optimal signal-to-noise ratios were obtained by
hybridizing test (tumour) and reference (normal colon)
DNA of similar quality, which was determined by giving
similar yield in a Bioscore Screening and Amplification
kit (ENZO diagnostics Inc., Farmingdale, USA). For
hybridization, 500 ng of amplified DNA from test and
reference samples were labelled with Cy3 and Cy5, re-
spectively, using random-primed labelling (Bioprime
genomic DNA labelling kit, Invitrogen, Breda, the
Netherlands), and hybridized for 48 hours at 42°C using
a MAUI hybridization system (Biomicro Systems, Salt
Lake City, USA). After washing, arrays were scanned in
an Axon Genepix 4200AL microarray scanner. The
NimbleScan 2.4 software package (NimbleGen Systems
Inc., Madison, USA) was used to calculate log2 ratios
after performing spatial correction, normalization and a
25 kb average smoothing window on the data. Further
data interpretation and CNA calling was done with
Nexus Copy Number 5.0 software (Biodiscovery, El
Segundo, USA) using the Rank Segmentation Algorithm.
In 26 patients, hybridizations were performed against
normal DNA from the same patient to normalize for
germline copy number changes. In the other 8 cases,
germline copy number changes were excluded using
both public (http://projects.tcag.ca/variation/) and pri-
vate CNA databases. The cut-off value for gene copy
number gain and loss were manually set for each sample
to adjust for differences in signal strength and incor-
rectly centered baselines.
Prevalence of KRAS locus gene copy number changes
In order to assess the clinical relevance in terms of
prevalence of KRAS gene copy number changes in
mCRC patients, we assessed the KRAS gene copy num-
ber status in FFPE primary tumour tissue of 225 unse-
lected mCRC patients who participated to our previous
phase III study which did not involve the use of tar-
geted agents [37]. In these patients a 250 k oligonucleo-
tide array CGH was performed as previously described
[25].
Multiplex Ligation-dependent Probe Amplification (MLPA)
MLPA was performed according to the manufacturer’s
instruction using the SALSA P145-A2 kit (MRC
Holland, Amsterdam, the Netherlands), containing 40
probes including the 12p12.1 KRAS probe. Briefly,
200 ng DNA was denatured and allowed to hybridize for
16 h at 60°C in a thermocycler. Then SALSA Ligase-65
enzyme was added and ligation was allowed at 54°C.
After heat inactivation of the ligase enzyme at 98°C, pri-
mers, dNTPs and polymerase were added and PCR amp-
lification was performed for 35 cycles (60s at 95°C, 30s
at 60°C, and 90s at 72°C). Reactions were performed on
a PTC 200 thermal cycler (MJ Research Inc., Waltham,
Massachusetts, USA). One microliter of PCR product
was analysed by capillary electrophoresis on an ABI
3730 Analyzer (Applied Biosystems), and quantitative
data were obtained by Genemapper analysis (Applied
Biosystems).
MLPA data analysis
For each tumour sample, the peak area of the 12p12.1
and reference probes were determined in duplicate for
further analysis. The reference peak area was obtained
from blood samples from three different individuals,
each of which were analysed at least two times inde-
pendently. In every sample, for every probe, a tumour to
normal DNA copy number ratio was calculated by divid-
ing the median area under the peak for the 12p12.1
probe by the value for the reference DNA. Subse-
quently, all ratios were normalized by setting the me-
dian tumour to normal DNA copy number ratio of the
reference genes in de probe mixture to 1.0. A ratio
lower than 0.8 was considered a loss and a ratio higher
than 1.2 a gain.
MiRNA selection
Selection of miRNAs regulating KRAS was performed
using PicTar (http://pictar.mdc-berlin.de/), Target-
Scan (http://www.targetscan.org/) and miRNA targets
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(http://cbio.mskcc.org/mirnaviewer/). Venn diagram
analysis was used to select 14 miRNAs who were identi-
fied by at least two algorithms (Additional file 1: Figure
S1). In addition to the prediction programs we also
selected six extra miRNAs (Let-7, miR-18a, miR-21,
miR-133a, miR-133b, miR-205) which have been shown
to target KRAS in previous studies [30,33,38], resulting
in a total test series of 20 miRNAs. Two Taqman micro-
RNA assay were not available (mir-18a, mir-200c),
resulting in 18 miRNAs to analyze.
Total RNA extraction, miRNA reverse transcription and
real-time PCR
Total RNA was isolated from FFPE tissue of 34 pri-
mary tumours and matched normal tissue using the
RecoverAll™ Total Nucleic Acid Isolation Kit (Ap-
plied Biosystems, Foster city, USA). In brief, four tis-
sue slices of 20 μm were micro dissected and
incubated with 100% xylene at 50°C to remove paraf-
fin excess, followed by ethanol washes. Proteins were
degraded by protease at 50° and 80°C. The RNA was
extracted followed by nuclease digestion. Total RNA
quantity and quality were determined using the Nanodrop
26 ND-1000 spectrophotometer (Nanodrop Technologies
Inc., Wilmington, USA).
To determine the expression levels of miRNAs,
Taqman microRNA assays directed to seventeen miR-
NAs and the endogenous reference gene (RNU 6B) were
used following the manufacture’s protocol (Applied Bio-
systems, Foster City, USA). Firstly, cDNA was synthe-
sized in duplicate from total RNA using miRNA specific
stem loop primers. Reverse transcriptase reactions were
conducted using 10 ng total RNA, 1 mM dNTPs, 50 U
MultiScribeTM Reverse Transcriptase, 1 x RT buffer, 3.8
U RNase inhibitor and 1 x TaqmanW MicroRNA RT Pri-
mer (Applied Biosystems, Foster city, USA). The 15 μl
reactions were incubated at 16°C for 30 minutes at 42°C
for 30 minutes and at 85°C for 5 minutes.
Secondly, the quantitative PCR was performed in
which the total mixture of 20 μl included 1.33 μl RT
product (1:5 diluted from RT reaction), 1 x TaqmanW
Universal PCR Master Mix (No AmpEraseW UNG, Ap-
plied Biosystems, Foster City, USA) and 1 x the dedi-
cated primer and probe mix. The reactions were
incubated in a 96-well optical plate at 95°C for 10 min-
utes, followed by 40 cycles at 95°C for 15 seconds and at
60°C for 1 minute. All reactions were carried out in du-
plicate in a 7500 Real Time PCR System (Applied Bio-
systems, Foster City, USA). The threshold cycle (Ct) was
defined as the fractional cycle number at which the
fluorescence passes the fixed threshold. Relative quantifi-
cation of miRNA expression was calculated using the
ΔΔCt method as described previously [39].
Statistical analysis
PFS was defined as the interval from the date of
randomization to the date of first documented disease
progression or death, whichever occurred first. Statis-
tical differences of clinical and pathological parameters
between good and poor responders were evaluated
using the Student’s t-test, Pearson’s χ2 test or Fisher’s
exact test where appropriate. The miRNA expression
in colorectal tumours was described by the relative
quantity (RQ) of the target miRNA, normalized in re-
spect to RNU6B and relative to matched normal tis-
sue. Box plots were used to appreciate the descriptive
statistics of the data. Differences in expression of the
target miRNA between good and poor responders were
evaluated on the log scale (ΔΔCt scale) to obtain nor-
mally distributed data. The Student’s t-tests was used
in exploratory analyses on the miRNA expression in
relation to response and to KRAS mutation status.
When focusing on the actually observed PFS, we
investigated by Cox regression analysis the influence of
each miRNA on PFS, using KRAS mutation status, the
interaction term between miRNA and KRAS mutation,
and differentiation grade as covariates. Due to the lim-
ited number of patients and the ensuing risk for over-
fitting, it was not possible to assess the influence of all
miRNAs together (i.e. correct the influence of miRNA
for each other), nor to correct for other baseline
characteristics.
Results
Patients
Of the 34 patients selected for this analysis, the median
PFS was 22.5 months (range 14.8-39.8 months) in the
17 good responders, and 6.0 months (range 2.3-
7.2 months) in the 17 poor responders. Clinical and
pathological characteristics of the primary tumour were
well balanced between the 17 good and 17 poor
responders. Only poor differentiation grade of the pri-
mary tumour was more frequently observed in the poor
responders.
A KRAS mutation was demonstrated in the primary
tumour of 15 patients (6 good responders and 9 poor
responders), and KRAS wild-type in the primary tumour
of 19 patients (11 good responders and 8 poor respon-
ders). KRAS codon 12 mutation was observed in 14
patients, and one poor responder had a codon 13 muta-
tion. Of the KRAS wild-type patients, 4 had a BRAF
mutated tumour (1 good responder and 3 poor respon-
ders) (Table 1).
12p12.1 copy number changes in good and
poor responders
By using high resolution array CGH, two copy number
gains (of which one amplification) and 5 losses were
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detected at the 12p12.1 locus where KRAS is localized
(Additional file 2: Figure S2). Both copy number gains,
which were confirmed by MLPA, were observed in poor
responders with a KRAS wild-type tumour. Of these
tumours one sample contained a gain of the complete p-
arm of chromosome 12 and the other sample contained
a high copy number gain of a region including the KRAS
locus.
A 12p12.1 copy number loss, detected by array CGH,
was observed in the tumour of 5 patients with a good re-
sponse. One tumour contained a loss of the whole
chromosome, three tumours included a loss of the short
arm of the chromosome and one tumour contained a
loss of a 27.5 Mb region of the short arm of chromo-
some 12 including the KRAS locus (Additional file 2:
Figure S2). Of these 5 tumours with loss of the 12p12.1
locus, 2 tumours harboured a KRAS mutation, and one
tumour had a BRAF mutation, suggesting that the mech-
anism of gene copy number loss is independent of the
KRAS and BRAF mutation status (Figure 1).
12p12.1 gene copy number changes in a control group of
mCRC patients
In an unselected group of 222 mCRC patients from our
previous trial with comparable baseline characteristics
[37], the prevalence of 12p12.1 copy number changes
Figure 1 12p12.1 copy number changes in good and poor
responders according to the KRAS mutation status. Abbreviations:
CNA= copy number aberration. MT = mutant, WT = wild-type.
Table 1 Clinical and histopathological characteristics of patients and their respective tumours
All eligible patients
n = 34
Good responders
n =17
Poor responders
n =17
p-value
Age Mean 58.6 58.0 59.2 0.07
Gender Female 14 (41%) 5 (29%) 9 (53%) 0.30
Male 20 (59%) 12 (71%) 8 (47%)
Number of metastatic sites 1 17 (50%) 9 (53%) 8 (47%) 0.60
>1 17 (50%) 8 (47%) 9 (53%)
WHO PS 0 23 (68%) 11 (65%) 12 (71%) 0.71
1 11 (32%) 6 (35%) 5 (29%)
Site of primary tumour Colon 22 (65%) 11 (65%) 11 (65%) 0.90
Rectosigmoid 12 (35%) 6 (35%) 6 (35%)
T stage 1-2 4 (12%) 2 (12%) 2 (12%) 0.49
3 21 (62%) 12 (71%) 9 (53%)
4 9 (26%) 3 (18%) 6 (35%)
N stage 0 9 (26%) 4 (24%) 5 (29%) 0.61
1 8 (24%) 4 (24%) 4 (24%)
2 14 (41%) 9 (53%) 5 (29%)
Unknown 3 (9%) 0 3 (18%)
Differentiation grade Good 1 (3%) 1 (6%) 0 0.02
Moderate 23 (68%) 15 (88%) 8 (47%)
Poor 10 (29%) 1 (6%) 9 (53%)
BRAF mutation status Wild-type 30 (88%) 16 (94%) 14 (82%) 0.29
Mutant 4 (12%) 1 (6%) 3 (18%)
KRAS mutation status Wild-type 19 (56%) 11 (65%) 8 (47%) 0.30
Mutant 15 (44%) 6 (35%) 9 (53%)
KRAS mutation type Codon 12 14 (93%) 6 (100%) 8 (89%) 0.40
Codon 13 1 (7%) 0 1 (11%)
PFS (months) Median (range) 11.0 (2.3-39.8) 22.5 (14.8-39.8) 6.0 (2.3-7.2) <0.0001
Abbreviations: PS = performance status, PFS = progression-free survival.
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was assessed. In this group three amplifications (1.4%),
32 copy number gains (14.4%), and 12 losses (5.4%) of
the 12p12.1 locus were observed. There was no effect of
KRAS copy number gain or loss on prognosis in these
patients treated with first-line chemotherapy without
cetuximab (p = 0.97 and p = 0.75, respectively, data not
shown).
MiRNA expression in good and poor responders
To assess the role of miRNA expression in relation to
clinical outcome, the expression levels of 18 miRNAs
targeting KRAS were determined by real-time RT-PCR
in 32 primary colorectal tumours relative to their
matched normal tissue. Two patients (1 good and 1 poor
responder) were not accessible for miRNA expression
due to an insufficient RNA amount in normal mucosa.
MiR-205 expression was undetectable in both tumour
and normal mucosa, therefore 17 miRNAs were
included in our final analysis. By using NormFinder [40]
and GeNorm [41], the use of RNU6B as a reference gene
was justified.
The expression level of 14 miRNAs showed a trend to-
wards a higher expression in patients with a good re-
sponse compared to patients with a poor response,
however this trend was not statistically significant. MiR-
143, miR-133a and miR-133b expression was decreased
in patients with a good response, of which miR-143
showed a relative expression in good versus poor respon-
ders of 0.49 (p = 0.07) (Table 2).
MiRNA expression in good and poor responders
according to KRAS mutation status
In patients with a wild-type KRAS tumour, the expression
level of miR-181a showed a 1.87-fold increase in good
responders compared to poor responders (p= 0.04), which
was not observed in patients with mutated KRAS tumours
(0.91-fold increase, p = 0.69). A higher expression of miR-
NAs in wild-type KRAS good responders compared with
wild-type KRAS poor responders was also observed for
MiR-200b (2.48-fold increase, p = 0.01) and miR-21 (1.66-
fold increase, p = 0.06).
A difference between the expression of miR-143 in
good versus poor responders was more obvious in
mutated KRAS tumours. The relative expression level of
miR-143 showed a 0.30 fold increase in mutated KRAS
good responders versus mutated KRAS poor responders
(p = 0.11) (Figure 2).
Multivariate model of PFS in relation to miRNA
expression and KRAS mutation status
Each miRNA was analyzed individually together with
differentiation grade as a covariate for PFS in wild-type
KRAS and mutated KRAS patients treated with first-line
cetuximab-containing therapy (Table 3). Differentiation
grade was used as a covariate in the Cox regression
model because this pathological feature is a well known
prognostic factor and differentially distributed between
good and poor responders.
Elevated expression of mir-200b was associated with a
better PFS in patients with a mutated KRAS tumour (HR
Table 2 MiRNA expression in good versus poor responders
Good responders Poor responders RQ Good versus poor P value
Mean ddCt SE RQ Mean ddCt SE RQ
MiR-27b −0.98 0.77 1.98 −0.92 0.64 1.90 1.04 0.80
MiR-105 −1.04 2.80 2.05 0.57 3.15 0.68 3.01 0.21
MiR-155 −0.66 1.25 1.58 −0.19 0.89 1.14 1.39 0.24
MiR-346 0.32 1.52 0.80 0.57 1.14 0.67 1.19 0.60
MiR-181a −1.64 0.85 3.11 −1.27 0.75 2.42 1.29 0.21
MiR-19a −3.39 1.84 10.45 −2.82 1.55 7.04 1.48 0.35
MiR-200b −0.57 0.92 1.49 0.05 1.42 0.97 1.54 0.15
MiR-27a −2.10 0.98 4.27 −2.00 0.82 4.00 1.07 0.77
MiR-30a −0.81 0.86 1.75 −0.66 0.88 1.58 1.11 0.65
Let-7a −0.67 0.79 1.59 −0.39 0.70 1.31 1.21 0.30
MiR-21 −3.16 1.16 8.92 −2.75 0.79 6.75 1.32 0.26
MiR-96 −4.56 1.32 23.59 −3.81 1.40 14.04 1.68 0.13
MiR-143 −0.73 1.35 1.66 −1.76 1.55 3.38 0.49 0.07
MiR-217 −2.91 3.09 7.53 −1.64 3.10 3.12 2.41 0.30
MiR-133a 0.91 1.69 0.53 0.33 1.79 0.79 0.67 0.36
MiR-133b 0.98 1.74 0.51 0.39 2.23 0.76 0.67 0.41
MiR-19b −2.95 1.71 7.73 −2.45 1.37 5.45 1.42 0.37
Abbreviations: SE = standard error, RQ = relative quotient.
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0.56 (0.28-1.15); p = 0.10). This trend was not present in
patients with a wild-type KRAS tumour. Surprisingly,
increased expression of miR-143 resulted in a shorter
PFS in patients with a mutated KRAS tumour (HR 1.59
(1.01-2.50); p = 0.04). The hazard ratio for PFS was not
influenced by miR-143 expression in wild-type KRAS
tumours.
Discussion
We demonstrated that regulation of the KRAS oncogene
at several levels might affect clinical outcome in a
selected group of cetuximab-treated mCRC patients
treated in a phase III trial [34]. Copy number loss of the
KRAS locus was restricted to good responders, whereas
a copy number gain was associated with a poor PFS in
patients with wild-type KRAS tumours. Increased ex-
pression of miR-200b that targets KRAS was associated
with improved PFS in patients with a mutated KRAS
tumour. Surprisingly, decreased miR-143 expression was
correlated with improved PFS in these patients.
The predictive strength of KRAS mutation status stres-
ses the importance of RAS-GTPase activity for the re-
sponse to cetuximab. Therefore, other regulatory
mechanisms of RAS-GTPase activity are obvious novel
candidate markers. CNA of the KRAS locus occur inde-
pendently of the KRAS mutation status in a considerable
percentage of colorectal tumours (21.2%) as assessed in
a large and unselected mCRC population. Previously, it
has been shown that KRAS copy number gains are cor-
related with increased RAS-GTPase activity in colorectal
cell lines and with worse clinical outcome in lung adeno-
carcinomas [27]. Our results suggest that KRAS copy
number gains are associated with worse clinical outcome
in wild-type KRAS mCRC patients who are treated with
a cetuximab-containing first-line regimen. This influence
of KRAS copy number gain on prognosis was absent in
mCRC patients treated without cetuximab, suggesting a
predictive effect on cetuximab response. The correlation
between miRNAs targeting KRAS and PFS was absent in
wild-type KRAS patients. Inhibition of KRAS translation
by miRNAs is probably only relevant when the KRAS
Figure 2 Box plots of the expression levels of miR-181a, miR-200b and miR-143 in mCRC patients according to clinical outcome and
KRAS mutation status. Abbreviations: G = good responders, P = poor responders, MT=mutant, WT=wild-type.
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expression levels are high, which is not the case in ab-
sence of an activating KRAS mutation.
KRAS mutations occur in approximately 38% of mCRC
patients [7], and these patients are currently excluded
from treatment with anti-EGFR antibodies. However, in
our selected good responders, 6 patients (35%) had a
KRAS mutated tumour. A recent publication showed that
patients with codon 13-mutated tumours might benefit
from cetuximab treatment [8]. In the current series none
of the good responders had a tumour with a KRAS codon
13 mutation. Our data show that the presence of KRAS
copy number loss in two of the mutated KRAS mCRC
patients might justify treatment with cetuximab. Dec-
reased expression of KRAS caused by loss of gene copies
in correlation with response to cetuximab has not been
described earlier. Despite the limitations in sample size
and concomitant treatment our results indicate that
patients with KRAS copy number loss might benefit from
treatment with an anti-EGFR antibody although their
tumour is KRAS mutated.
Next, we demonstrated that increased expression of
miR-200b was associated with improved PFS in mutated
Table 3 A multivariate model in which each miRNA was analyzed individually together with differentiation grade as a
predictor for PFS in wild-type-KRAS and mutated-KRAS patients treated with chemotherapy, bevacizumab and
cetuximab
Overall
n = 32
KRAS wild-type
n= 18
KRAS mutation
n= 14
p-value
MiR-27b HR (95% CI) 0.74 (0.38-1.42) 0.94 (0.36-2.42) 0.51 (0.20-1.32) 0.38
p-value 0.36 0.89 0.16
MiR-105 HR (95% CI) 1.04 (0.84-1.29) 0.95 (0.76-1.21) 1.22 (0.83-1.78) 0.26
p-value 0.72 0.69 0.32
MiR-155 HR (95% CI) 0.92 (0.62-1.35) 0.77 (0.38-1.53) 0.96 (0.60-1.51) 0.60
p-value 0.66 0.45 0.85
MiR-346 HR (95% CI) 0.83 (0.63-1.10) 0.85 (0.61-1.19) 0.72 (0.40-1.32) 0.63
p-value 0.20 0.34 0.29
MiR-181a HR (95% CI) 0.75 (0.46-1.22) 0.70 (0.37-1.33) 0.94 (0.44-2.02) 0.57
p-value 0.24 0.27 0.87
MiR-19a HR (95% CI) 0.96 (0.78-1.19) 1.03 (0.80-1.33) 0.74 (0.45-1.20) 0.23
p-value 0.73 0.82 0.22
MiR-200b HR (95% CI) 1.03 (0.72-1.47) 0.90 (0.51-1.57) 1.78 (0.87-3.62) 0.18
p-value 0.86 0.70 0.10
MiR-27a HR (95% CI) 0.74 (0.43-1.27) 0.69 (0.31-1.54) 0.71 (0.35-1.43) 0.96
p-value 0.27 0.37 0.34
MiR-30a HR (95% CI) 0.70 (0.44-1.10) 0.77 (0.40-1.55) 0.70 (0.37-1.34) 0.86
p-value 0.12 0.46 0.28
Let-7a HR (95% CI) 0.94 (0.59-1.50) 0.89 (0.50-1.59) 1.28 (0.46-3.58) 0.55
p-value 0.80 0.68 0.63
MiR-21 HR (95% CI) 0.89 (0.57-1.39) 1.15 (0.52-2.55) 0.81 (0.49-1.33) 0.47
p-value 0.61 0.74 0.40
MiR-96 HR (95% CI) 0.84 (0.59-1.20) 0.74 (0.45-1.22) 0.93 (0.55-1.58) 0.54
p-value 0.33 0.24 0.79
MiR-143 HR (95% CI) 0.73 (0.51-1.05) 0.92 (0.56-1.51) 0.63 (0.40-0.99) 0.26
p-value 0.09 0.74 0.04
MiR-217 HR (95% CI) 1.01 (0.87-1.16) 0.85 (0.61-1.19) 0.78 (0.56-1.08) 0.72
p-value 0.95 0.34 0.13
MiR-133a HR (95% CI) 0.81 (0.63-1.05) 0.98 (0.68-1.43) 0.66 (0.41-1.06) 0.21
p-value 0.12 0.92 0.09
MiR-133b HR (95% CI) 0.89 (0.70-1.13) 1.04 (0.73-1.49) 0.80 (0.55-1.17) 0.32
p-value 0.32 0.83 0.25
MiR-19b HR (95% CI) 0.95 (0.75-1.20) 1.02 (0.77-1.34) 0.66 (0.36-1.23) 0.21
p-value 0.65 0.91 0.19
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KRAS patients. We hypothesize that reducing KRAS
protein levels in the presence of a mutation might im-
prove clinical outcome in patients treated with cetuxi-
mab. KRAS is not the only target of the miR-200 family,
miR-200b is also capable of reducing ERRFI-1 mRNA
and subsequent activation of EGFR [42]. Adam et al.
showed that increased expression of miR-200b facilitates
optimal EGFR functionality, resulting in an efficient re-
sponse of bladder cancer cells to cetuximab. To our
knowledge, our results are the first data in vivo suggest-
ing that in the presence of a KRAS mutation, an
increased miR-200b expression is associated with an
improved PFS in cetuximab-treated mCRC patients. Sur-
prisingly a decreased expression of miR-143 was asso-
ciated with improved PFS in patients with mutated
KRAS tumours. MiR-143 is thought to inhibit KRAS
translation and thereby to suppress tumour cell growth
during tumourigenesis [32]. In an established tumour,
modulation of KRAS by miR-143 may be differentially
regulated which could possibly explain our findings.
However, since miRNAs are capable of repressing over a
hundred different mRNAs [28], miR-143 could also tar-
get mRNAs which may be relevant in response to cape-
citabine, oxaliplatin and bevacizumab. Previous studies
on biomarkers have shown divergent results which stres-
ses the importance of the results of our current
hypothesis-generating study being confirmed in a larger,
independent series of mCRC patients preferably treated
with cetuximab monotherapy.
The patients used in this study were derived from a
clinical trial, and the observed outcome is also influ-
enced by the effect of the other agents used. The relative
contribution of cetuximab to this outcome is therefore
unclear. The phase III CAIRO2 trial showed that cetuxi-
mab plus chemotherapy and bevacizumab resulted in a
significantly decreased median PFS compared to treat-
ment with chemotherapy and bevacizumab alone. The
explanation of this detrimental outcome is unclear [43],
and complicates the interpretation of the current ana-
lysis. Excessive toxicity in the cetuximab group does not
appear to be cause of these results. Negative interaction
between the antibodies or between antibodies and
chemotherapy might have influenced the outcome al-
though preclinical observations supporting this hypoth-
esis are not yet available. The interpretation of the
current analysis is complicated by the detrimental out-
come of the trial. Whether this outcome also affects the
PFS in the good responders remains unclear.
In conclusion, the analysis of KRAS CNA and miRNAs
targeting KRAS may optimize the selection of mCRC
patients eligible for anti-EGFR therapy. Elevated expres-
sion of miR-200b, decreased miR-143 level and copy
number losses may identify patients with mutated KRAS
tumours who benefit from anti-EGFR therapy, whereas
copy number gains in wild-type KRAS patients could
predict resistance to cetuximab. Our results are relevant
for the development of predictive biomarkers for anti-
EGFR therapy, and suggest that the clinical effects of
KRAS are the result of a complex interaction of several
regulatory mechanisms beyond the KRAS point muta-
tion status.
Conclusions
KRAS activity, an important regulator of response to
anti-EGFR therapy, can be influenced by genetic and
epigenetic regulation. CNA and specific miRNAs may
provide important additional information to KRAS mu-
tation status and their use could further improve the se-
lection of mCRC patients for anti-EGFR therapy. The
hypothesis-generating nature of our study urges for our
results to be confirmed in larger series.
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